DNER and small cell lung carcinoma: A BET inhibitor, JQ-1, has been used in multiple studies for the treatment of Cushing’s disease and SCLC with the main implication of treatment being ASCL1 downregulation, suppression of its activity and downstream targets [90,91]; therefore, this could be a therapeutic avenue for the exploration of NEPC treatment.